The Global Antibiotic Research and Development Partnership (GARDP) has launched a stage-three trial of zoliflodacin, a potential new antibiotic to treat gonorrhoea, in South Africa as well as the United States, the Netherlands and Thailand.
The World Health Organisation started the GARDP in 2016. It is a non-profit organisation focused on developing new treatments for infections which have become resistant to available treatments. It says its mission is to produce new medicines which are accessible and affordable to all who need them.
Zoliflodacin is being trialled at three sites in South Africa – the Wits Reproductive Health and HIV Institute based at the Hillbrow Health Precinct in Johannesburg, and two South African Medical Research Council sites at Tongaat and Botha’s Hill in KwaZulu-Natal.
United-states
Thailand
Netherlands
Hillbrow
Gauteng
South-africa
Tongaat
Kwazulu-natal
Johannesburg
Kwazulu
Eastern-cape
Natal